Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$1.00 +2.1%	$0.98	$0.61 ▼ $7.45	$15.08M	-0.15	1.14 million shs	294,547 shs
ATNF 180 Life Sciences	$0.83 -4.3%	$1.01	$0.66 ▼ $17.75	$4.73M	0.23	798,622 shs	26,480 shs
LPCN Lipocine	$3.29 +2.2%	$3.30	$2.68 ▼ $8.71	$17.60M	1.34	32,965 shs	34,791 shs
MIRA MIRA Pharmaceuticals	$1.25 +2.9%	$1.22	$0.51 ▼ $5.01	$21.07M	1.96	2.21 million shs	76,588 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	0.00%	+7.52%	+12.15%	-3.86%	-83.42%
ATNF 180 Life Sciences	0.00%	-3.96%	-19.02%	-19.42%	-45.75%
LPCN Lipocine	0.00%	-0.30%	-1.79%	+0.30%	-58.09%
MIRA MIRA Pharmaceuticals	0.00%	+2.05%	-7.09%	+17.45%	+76.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Earnings & Valuation
ALLR Allarity Therapeutics	0.7852 of 5 stars	0.0	4.0	1.4	1.3
ATNF 180 Life Sciences	1.0482 of 5 stars	0.0	5.0	2.6	0.6
LPCN Lipocine	2.1802 of 5 stars	3.5	3.0	2.3	0.6
MIRA MIRA Pharmaceuticals	2.9185 of 5 stars	3.7	5.0	2.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLR Allarity Therapeutics	0.00	N/A	N/A	N/A
ATNF 180 Life Sciences	0.00	N/A	N/A	N/A
LPCN Lipocine	3.00	Buy	$9.00	173.56% Upside
MIRA MIRA Pharmaceuticals	3.33	Buy	$14.00	1,024.50% Upside

Current Analyst Ratings Breakdown

Latest ATNF, ALLR, LPCN, and MIRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/27/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/11/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/10/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
5/29/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$8.00
5/24/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/10/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/24/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/8/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	$1.62 per share	N/A
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	$2.91 per share	N/A
LPCN Lipocine	$11.20M	1.57	N/A	N/A	$3.93 per share	0.84
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.13 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLR Allarity Therapeutics	-$24.51M	N/A	0.00	N/A	N/A	N/A	-147.94%	-90.33%	8/4/2025 (Estimated)
ATNF 180 Life Sciences	-$6.17M	N/A	0.00	∞	N/A	N/A	-147.32%	-76.99%	8/11/2025 (Estimated)
LPCN Lipocine	$10K	-$1.02	N/A	∞	N/A	N/A	-26.68%	-24.77%	8/6/2025 (Estimated)
MIRA MIRA Pharmaceuticals	-$7.85M	-$0.51	N/A	N/A	N/A	N/A	-341.08%	-272.93%	8/12/2025 (Estimated)

Latest ATNF, ALLR, LPCN, and MIRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ATNF 180 Life Sciences	N/A	-$0.67	N/A	-$0.67	N/A	N/A
5/14/2025	Q1 2025	MIRA MIRA Pharmaceuticals	-$0.15	-$0.11	+$0.04	-$0.11	N/A	N/A
5/13/2025	Q1 2025	ALLR Allarity Therapeutics	-$8.10	-$0.25	+$7.85	-$0.25	N/A	N/A
5/8/2025	Q4 2024	LPCN Lipocine	-$0.35	-$0.35	N/A	-$0.35	$0.35 million	$0.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	N/A
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLR Allarity Therapeutics	N/A	2.66	2.66
ATNF 180 Life Sciences	N/A	1.02	1.02
LPCN Lipocine	N/A	15.64	15.64
MIRA MIRA Pharmaceuticals	N/A	12.86	12.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLR Allarity Therapeutics	11.53%
ATNF 180 Life Sciences	4.07%
LPCN Lipocine	9.11%
MIRA MIRA Pharmaceuticals	35.16%

Insider Ownership

Company	Insider Ownership
ALLR Allarity Therapeutics	0.08%
ATNF 180 Life Sciences	0.17%
LPCN Lipocine	6.35%
MIRA MIRA Pharmaceuticals	6.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLR Allarity Therapeutics	10	15.08 million	15.07 million	Not Optionable
ATNF 180 Life Sciences	7	5.70 million	5.69 million	No Data
LPCN Lipocine	10	5.35 million	5.01 million	No Data
MIRA MIRA Pharmaceuticals	2	16.92 million	15.80 million	Not Optionable

ATNF, ALLR, LPCN, and MIRA Headlines

Recent News About These Companies

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - El Paso Times

June 26 at 7:37 PM | elpasotimes.comE

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - The Des Moines Register

June 26 at 7:37 PM | desmoinesregister.comD

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking ... - The Columbus Dispatch

June 26 at 7:37 PM | dispatch.com

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - Milwaukee Journal Sentinel

June 26 at 7:37 PM | jsonline.comJ

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - Courier-Journal

June 26 at 7:37 PM | courier-journal.comC

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - azcentral.com

June 26 at 7:37 PM | azcentral.comA

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking ... - Asbury Park Press

June 26 at 7:37 PM | app.comA

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - The Journal News or lohud.com

June 26 at 7:37 PM | lohud.comL

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without ...

June 26 at 12:11 PM | finanznachrichten.de

MIRA Announces Positive Test Results from Acquisition

June 26 at 2:42 AM | finance.yahoo.com

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 – A Drug Candidate Pending Acquisition – To Disrupt Weight Loss and Smoking Cessation Markets ...

June 25, 2025 | tennessean.comT

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects

June 25, 2025 | accessnewswire.comA

MIRA Gets Validation from Journal

June 18, 2025 | finance.yahoo.com

MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology

June 18, 2025 | accessnewswire.comA

MIRA Pharmaceuticals’ Ketamir-2 Published in Pharmacology Journal

June 17, 2025 | tipranks.com

Visionstate Launches MIRA to Digitize Facility Inspections and Expand SaaS Platform

June 5, 2025 | thenewswire.comT

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program

May 28, 2025 | accessnewswire.comA

MIRA Pharmaceuticals Appoints New Chief Financial Officer

May 21, 2025 | tipranks.com

MIRA Releases Financials as Research Continues

May 15, 2025 | finance.yahoo.com

MIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60M

May 9, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNF, ALLR, LPCN, and MIRA Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

$1.00 +0.02 (+2.12%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.00 +0.01 (+0.51%)

As of 06/27/2025 07:59 PM Eastern

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

180 Life Sciences NASDAQ:ATNF

$0.83 -0.04 (-4.27%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.84 +0.01 (+0.84%)

As of 06/27/2025 05:46 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Lipocine NASDAQ:LPCN

$3.29 +0.07 (+2.17%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.33 +0.04 (+1.25%)

As of 06/27/2025 07:58 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

MIRA Pharmaceuticals NASDAQ:MIRA

$1.25 +0.04 (+2.89%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.25 +0.01 (+0.72%)

As of 06/27/2025 08:00 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time